Apellis Pharmaceuticals, Inc.
APLSDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How APLS's past catalysts played out
APL-2, Pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular Degeneration
Pegcetacoplan
C3G
PEGCETACOPLAN (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-2
Paroxysmal Nocturnal Hemoglobinuria
Soliris
Paroxysmal Nocturnal Hemoglobinuria
APL-3007, pegcetacoplan (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-9
COVID
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
Pegcetacoplan | Phase 3 | C3G | - | - |
PEGCETACOPLAN (APL-2) | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-2 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Soliris | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-9 | Phase 2 | COVID | - | - |
Paroxysmal Nocturnal Hemoglobinuria
2 drugs in this indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
2 drugs in this indication
COVID
1 drug in this indication
C3G
1 drug in this indication
Complement 3 Glomerulopathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apellis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Apellis Pharmaceuticals, Inc.'s (APLS) pipeline across Phase 3, Phase 2. Its lead program is APL-2, Pegcetacoplan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apellis Pharmaceuticals, Inc.'s next FDA catalyst?→
Apellis Pharmaceuticals, Inc.'s (APLS) next tracked catalyst is a Phase 2 expected June 25, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APLS biotech catalysts?→
Add APLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apellis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.